Bolus

American Regent Introduces Potassium Phosphates, USP; FDA-Approved and "AP" Rated¹

Retrieved on: 
Thursday, October 19, 2023

In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.

Key Points: 
  • In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.
  • Vein Damage and Thrombosis: Potassium Phosphates Injection must be diluted and administered in intravenous fluids or used as an admixture in parenteral nutrition.
  • You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
  • You are encouraged to report adverse drug events (ADEs) to American Regent:
    ADEs may also be reported to the FDA:

3D Systems Partners with Klarity to Expand Access to Patient-Matched Radiotherapy Innovations

Retrieved on: 
Wednesday, September 27, 2023

Klarity will offer VSP Bolus within its new line of high-quality patient-specific 3D printed products called Klarity Prints™.

Key Points: 
  • Klarity will offer VSP Bolus within its new line of high-quality patient-specific 3D printed products called Klarity Prints™.
  • Klarity Prints, powered by 3D Systems, is a service-based line of 3D-printed radiotherapy accessories such as VSP Bolus, which does not require specialized software or hardware, allowing radiotherapy providers to focus on patient care.
  • 3D Systems developed VSP Bolus to deliver 3D-printed, biocompatible, patient-specific boluses that can improve therapy modulation, decrease technician time, and enhance patient comfort.
  • Through the distribution agreement with Klarity, this innovative 3D-printed solution is now available to radiotherapy clinics across the United States and Canada.

Individuals Who Paid a Parking Fine to the Parking Authority of River City ("PARC") Could Be Affected by a Class Action

Retrieved on: 
Monday, September 18, 2023

The Jefferson County, Kentucky Circuit Court has certified a class action against the Parking Authority of River City, Inc. ("PARC").

Key Points: 
  • The Jefferson County, Kentucky Circuit Court has certified a class action against the Parking Authority of River City, Inc. ("PARC").
  • Plaintiffs claim that the Defendant, PARC, unlawfully collected parking fines and related penalties from January 1, 2002, through December 31, 2008.
  • Individuals are included if they paid one or more parking tickets more than 7 days after receiving the ticket from the Louisville/Jefferson County Parking authority (PARC) during 2002–2008.
  • Write to: PARC Class Action, c/o Rust Consulting Inc – 6347, PO Box 2599, Faribault, MN 55021-9599

Insulet Celebrates One Year of Omnipod® 5 at the American Diabetes Association 83rd Scientific Sessions

Retrieved on: 
Thursday, June 22, 2023

“Insulet’s flagship product, Omnipod 5, is having an incredible impact on people with diabetes, including improved glycemic outcomes and better quality of life,” said Jim Hollingshead, Insulet President and CEO.

Key Points: 
  • “Insulet’s flagship product, Omnipod 5, is having an incredible impact on people with diabetes, including improved glycemic outcomes and better quality of life,” said Jim Hollingshead, Insulet President and CEO.
  • In order to provide smartphone control for customers who use iOS mobile technology, Insulet has submitted the Omnipod 5 App for iPhone to the FDA for 510(k) clearance.
  • The study will recruit up to 200 participants with type 1 diabetes in both the adult and pediatric age groups in the United Kingdom, France, and Belgium.
  • Special Gifts: Insulet is offering visitors a free professional headshot and refreshments after participating in an educational session and completing a brief survey.

Intertape Polymer Group Showcases Industry Leadership in 2021 Annual Sustainability Report

Retrieved on: 
Wednesday, July 20, 2022

MONTREAL and SARASOTA, Fla., July 20, 2022 (GLOBE NEWSWIRE) -- Leading packaging and protective solutions manufacturer Intertape Polymer Group Inc. ("IPG" or the "Company") today published its annual sustainability report, which catalogs the Companys 2021 sustainability impacts and furthers its commitments for the future.

Key Points: 
  • MONTREAL and SARASOTA, Fla., July 20, 2022 (GLOBE NEWSWIRE) -- Leading packaging and protective solutions manufacturer Intertape Polymer Group Inc. ("IPG" or the "Company") today published its annual sustainability report, which catalogs the Companys 2021 sustainability impacts and furthers its commitments for the future.
  • The report, titled Safe, Circular & Responsible, discloses IPGs annual sustainability performance and actions over the course of 2021, and identifies areas of further improvement as it continues to advance responsible manufacturing, environmental stewardship, and the well-being of its workforce.
  • The Companys customer-centric and sustainability-oriented commitment to do the right thing was elevated in 2021, despite the global economic challenges faced during the reporting period.
  • Highlights from the 2021 IPG Sustainability Report include:
    Fully adopted the Cradle to Cradle design principles.

3D Systems Announces VSP® Bolus to Optimize Radiotherapy Targeting, Improve Patient Experience

Retrieved on: 
Thursday, April 21, 2022

3D Systems deep experience in additive manufacturing of medical devices enables the company to deliver 3D-printed, biocompatible patient-specific boluses that can improve therapy modulation as well as patient comfort.

Key Points: 
  • 3D Systems deep experience in additive manufacturing of medical devices enables the company to deliver 3D-printed, biocompatible patient-specific boluses that can improve therapy modulation as well as patient comfort.
  • With VSP Bolus, 3D Systems can design and deliver boluses that conform to a wide range of anatomies.
  • Using this information, VSP Bolus is designed at the requested material thickness to optimize the radiotherapy targeting.
  • 3D Systems will showcase its solutions, including VSP Bolus, at the RSNA Medical 3D Printing in Practice event to be held April 22-24 in Chicago, Illinois.

Welldoc Receives Ninth 510(k) for Award-Winning Diabetes Platform, BlueStar®

Retrieved on: 
Wednesday, September 22, 2021

Welldoc , a digital health leader revolutionizing chronic care, today announced the receipt of its ninth 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes platform, BlueStar.

Key Points: 
  • Welldoc , a digital health leader revolutionizing chronic care, today announced the receipt of its ninth 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes platform, BlueStar.
  • The new clearance expands insulin dosing support to most types of insulin, including Bolus and Premixed Insulin titration for type 2 diabetes.
  • In June 2020, Welldoc announced FDA clearance for the BlueStar Insulin Adjustment Program for basal insulin titration.
  • Welldocs previous FDA clearances for its advanced Artificial Intelligence (AI) capabilities and enhanced product features support the companys continued efforts to simplify complex diabetes management.

Wearable Bolus Injectors: Balancing Stakeholder Needs and Overcoming Barriers to Entry, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, July 14, 2021

However, the market for such devices remains immature and faces persistent challenges from well-established autoinjectors and a new cohort of larger payload, more sustainable autoinjector variants.

Key Points: 
  • However, the market for such devices remains immature and faces persistent challenges from well-established autoinjectors and a new cohort of larger payload, more sustainable autoinjector variants.
  • Register for an upcoming webinar to hear Tony Bedford, Director, Front-End Innovation, Phillips-Medisize, a Molex company, discuss some of the challenges involved in developing a wearable bolus injector.
  • For more information or registration for this event, visit Wearable Bolus Injectors: Balancing Stakeholder Needs and Overcoming Barriers to Entry.
  • To learn more about Xtalks, visit http://xtalks.com
    For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/
    Ayesha Rashid, Xtalks, +1 (416) 977-6555 x 272, [email protected]

Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone

Retrieved on: 
Wednesday, May 19, 2021

The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.

Key Points: 
  • The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.
  • "Controlling an insulin pump and viewing its status via smartphone allows people with diabetes to use a device which is usually close at hand.
  • Using the mySugr Pump Control provides people with diabetes more discretion and simplicity with their everyday insulin pump therapy.
  • Users of the mySugr Pump Control are also able to get support from the mySugr Bolus Calculator, which calculates the needed amount of insulin for meal and correction boluses.

Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone

Retrieved on: 
Wednesday, May 19, 2021

The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.

Key Points: 
  • The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.
  • "Controlling an insulin pump and viewing its status via smartphone allows people with diabetes to use a device which is usually close at hand.
  • Using the mySugr Pump Control provides people with diabetes more discretion and simplicity with their everyday insulin pump therapy.
  • Users of the mySugr Pump Control are also able to get support from the mySugr Bolus Calculator, which calculates the needed amount of insulin for meal and correction boluses.